Evidence map›Paper›PMID 37688350›Full record

ArticleAdvanced biology2024

A Mouse Model to Investigate the Impact of Gender Affirming Hormone Therapy with Estradiol on Reproduction.

Daniel R Pfau, Amanda R Schwartz, Cynthia Dela Cruz, Vasantha Padmanabhan, Molly B Moravek, Ariella Shikanov

Open access · hybridAbstract read
In one paragraph

Article in Advanced biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Daniel R PfauDepartment of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, 48109, USA.ORCID 0000-0002-4510-647X
Amanda R SchwartzDepartment of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, 48109, USA.
Cynthia Dela CruzDepartment of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, 48109, USA.ORCID 0000-0002-1236-9142
Vasantha PadmanabhanDepartment of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, 48109, USA.
Molly B MoravekDepartment of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, 48109, USA.ORCID 0000-0001-9972-4938
Ariella ShikanovDepartment of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, 48109, USA.ORCID 0000-0003-0159-6419
University of Michigan · US

Funding

Strategic Vision & Impact on Environmental HealthP30ES017885 · NIEHS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Dana Dolinoy · 2011 to 2026
$21.3M
Testosterone-GnRH Frequency and the Evolution of PCOS in AdolescenceP50HD028934 · NICHD · UNIVERSITY OF VIRGINIA · PI HAISENLEDER, DANIEL J. · 2014 to 2018
$8.6M
Postdoc Stipend Supplement: Developmental Origins of Metabolic Disorders T32T32DK071212 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID P OLSON, Kanakadurga Singer · 2005 to 2026
$5.4M
Reproductive Consequences of Steroid Hormone AdministrationR01HD098233 · NICHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MORAVEK, MOLLY BENNETTE · 2019 to 2023
$2.6M
Eunice Kennedy Shriver P50-HD28934NICHD NIH HHS P50 HD028934NICHD NIH HHS R01 HD098233NIDDK NIH HHS T32 DK071212NIEHS NIH HHS P30 ES017885NIH HHS RO1 HD098233
6 · The paper itself

Abstract

Gender-affirming hormone therapy (GAHT) can help transgender and/or gender diverse (TGD) individuals achieve emobidment goals that align with their transition needs. Clinical evidence from estradiol (E)-GAHT patients indicate widespread changes in tissues sensitive to E and testosterone (T), particularly in the reproductive system. Notably, E-GAHTs effects on hormones and reproduction vary greatly between patients. With the goal of informing clinical research and practice for TGD individuals taking E, this study examines intact male mice implanted with capsules containing one of three different E doses (low 1.25 mg; mid 2.5 mg; high 5 mg), or a blank control capsule. All E-GAHT doses suppress T and follicle stimulating hormone levels while elevating E levels. Only the high E-GAHT dose significantly supresses luteinizing hormone levels. All E-GAHT doses affect epididymis tubule size similarly while seminiferous tubule morphology and bladder weight changes are dose-dependent. E-GAHT does not alter the presence of mature sperm, though E-exposed sperm have altered motility. These data represent the first evidence that mouse models offer an effective tool to understand E-GAHTs impact on reproductive health and the dose-dependent effects of this model permit examinations of diverse patient outcomes.

Indexed as

EstradiolReproductionTestosteroneAnimalsFemaleFollicle Stimulating HormoneHumansLuteinizing HormoneMaleMiceEstradiolFollicle Stimulating HormoneLuteinizing HormoneTestosteroneestrogenfertilitygender‐affirming hormonesgonadotropintestistestosteronetransgender

Identifiers

PMID37688350
PMCPMC10920391
OpenAlexW4386564772

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.